Languages ∨ Sian In Send a F

PR Newswire **Products** News Resources Contact Sea a cision company Multimedia **Public Company News** Latest Regional Industry **Trending Topics** Other Languages

## Cedrus Group's Chairman Mr. Rani Jarkas Invited to Speak the ANNUAL BIOPHARMA DEVELOPMENT AND PRODUCTION WFFK English ~

Cedrus Group 2020-09-01 09:00	Share:

CEDRUS 20 80 HONG KONG, Sept. 1, 2020 /PRNewswire/ -- The Chairman of Cedrus Group ("Cedrus"), Mr. Rani Jarkas, is invited to speak at the "6<sup>th</sup> Annual Biopharma Development and Production Week" conference to be held on 3<sup>rd</sup> - 5<sup>th</sup> November 2020. This year, the event will be conducted virtually in the face of the universal outbreak of COVID-19. The conference will connect key decision makers biopharma industry for exchanging views and information along with offering opportunities for potentially forging partnerships and co

Mr. Jarkas will be speaking at the "Show Me the Drugs" plenary session to share his extensive industry experience and profound insight: investment landscape, market development trajectory as well as the role of and new opportunities presenting to financial institutions a current changing environment driven in part by the COVID-19 epidemic.

For over two decades, Cedrus has been investing in the field of biopharma in addition to facilitating inbound and outbound investment transactions alongside cross-border collaborations involving its clients and companies from around the globe with a proven track record importantly, Cedrus closely monitors and analyzes the industry's development so as to identify innovative technologies with far-reachin and capitalize on unique investment opportunities globally in the life sciences industry.

Mr. Jarkas said, "I'm honored to be invited to attend this year's event, especially at a time when the biopharma industry is undergoing d changes. Despite increased uncertainty, Cedrus is still committed to bringing cutting-edge biopharma products and technologies to Ch benefit the health of Chinese people and the domestic industry in terms of promoting technological innovation and collaboration.

Moreover, Cedrus has established comprehensive relationships in both the public and private sectors, enabling it to actively participate contribute to the building a stronger and healthier China under the guidance of the country's relevant schemes, including the Healthy 2030 initiative, by virtue of Cedrus' extensive expertise and experience in the biopharma industry."

## **About Cedrus Group**

Cedrus Group is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advi Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions trac in geographies, including China, Australia, Asia, U.S., and Europe.

Media Enquiry:

Cedrus Group Amy Sin +852-3519-2828 information@cedrusinvestments.com

Logo - http://photos.prnasia.com/prnh/20150930/8521506461LOGO?lang=0

Source: Cedrus Group

Keywords: Banking/Financial Service Biotechnology Health Care/Hospital Medical/Pharmaceuticals Pharmaceuticals

Share:

## **Media Room**

Cedrus Investments Successfully Launched a New Office in Shenzhen, China

2020-03-23 09:00 @ 1234

Cedrus' Head of Life Sciences, Ms. Kimberly Nearing, in to moderate a panel at 2019 SAPA Healthcare Investn

2019-06-25 09:00 • 1730

Cedrus' Head of Life Sciences Invited to Moderate a Panel at China Focus@BIO and was a Panelist at the Redefining Earl...

2019-06-17 09:00 • 1562

Cedrus Investments launched new enhanced website

2019-06-11 09:00 • 1776

Cedrus Investments' Chairman Mr. Rani Jarkas is Invited to Speak at the Mines and Money Asia 2019 CONFERENCE

2019-03-26 11:59 • 1187

Cedrus' Head of Life Sciences, Ms. Kimberly Nearing ir to speak at the BIO CEO & Investor Conference in New

2019-03-04 09:00 • 1056

## **Related News**

Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th

TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study

InventisBio Announces \$147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures

2020-09-28 05:00 • 1201

Radius Health & Menarini Group Provide Elacestrant l

2020-09-25 18:15 • 4467

Qiming's Portfolio Company Zai Lab Lists on Main Board of **HKEX** 

2020-09-28 11:26 • 751

Preventative nasal spray shown to reduce viral replica up to 96% in COVID-19 challenge study

2020-09-28 06:00 • 1017

**Products** 

Content Creation Distribution Monitoring & Insights Influencer Database FAQs

About PR Newswire

About PR Newswire About Cision Careers

Global Sites ∧

Contact PR Newsw

hkcs@prnasia.com Contact Us ^

**y** f in

Conditions of Services | Site Map | RSS

Copyright © 2020 PR Newswire Asia Ltd. All Rights Reserved. A Cis